Long-acting therapies are anticipated to drive the human immunodeficiency virus (HIV) market, according to a report by GlobalData.

Titled ‘PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025’, the report identifies a lack of long-acting and safe treatments in the HIV market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Existing antiretroviral therapies (ART) use a combination of anti-retroviral drugs requiring a minimum of once-daily dosing. Adherence to these ARTs is a significant concern among patients.

GlobalData's healthcare analyst David Fratoni says: "Development of long-acting therapies that require intravenous injection once-a-month might address the problem, although it may not appeal to all patients."

"Development of long-acting therapies that require intravenous injection once-a-month might address the problem, although it may not appeal to all patients."

Pharmaceutical companies are increasing focus on addressing such unmet needs through collaborations. For example, ViiV and Janssen are developing a long-acting formulation of an integrase inhibitor (INI), cabotegravir, and non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.

See Also:

The report forecasts these long-acting formulations to replace the existing treatments. Although incarcerated and homeless patients may not find these formulations appealing, other patients who dislike taking more than one pill a day are likely to opt for such treatments, states Fratoni.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.